The stem cell wars

a dispatch from the front.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The development of human embryonic stem cell (hESC) lines in 1998 offered the prospect of a new era of regenerative medicine in which cell therapy might cure intractable diseases such as type 1 diabetes, Parkinson's disease, and spinal cord injury. The Bush Administration decision in 2001 to restrict federal funding of hESC research touched off a controversy that continues to the present. One response to the Bush policy was establishment of state stem cell research funding programs, notably the California Institute of Regenerative Medicine (CIRM). As Director of the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) and Vice Chair of the National Institutes of Health (NIH) Stem Cell Task Force, and now as a member of the Empire State Stem Cell Funding Board and member of an Institute of Medicine (IOM) committee charged with evaluation of the CIRM, I have had the opportunity to gain a first-hand perspective of the field. Here I present my impressions of the legal and science policy debates and selectively summarize research progress toward the hoped-for cures.

Original languageEnglish (US)
Pages (from-to)94-110
Number of pages17
JournalTransactions of the American Clinical and Climatological Association
Volume124
StatePublished - 2013

Fingerprint

Regenerative Medicine
Stem Cell Research
Stem Cells
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
National Institutes of Health (U.S.)
Advisory Committees
Cell- and Tissue-Based Therapy
Type 1 Diabetes Mellitus
Spinal Cord Injuries
Parkinson Disease
Cell Line
Research
Warfare
Human Embryonic Stem Cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The stem cell wars : a dispatch from the front. / Spiegel, Allen M.

In: Transactions of the American Clinical and Climatological Association, Vol. 124, 2013, p. 94-110.

Research output: Contribution to journalArticle

@article{664ade2e51e64591a7cad254dc153f37,
title = "The stem cell wars: a dispatch from the front.",
abstract = "The development of human embryonic stem cell (hESC) lines in 1998 offered the prospect of a new era of regenerative medicine in which cell therapy might cure intractable diseases such as type 1 diabetes, Parkinson's disease, and spinal cord injury. The Bush Administration decision in 2001 to restrict federal funding of hESC research touched off a controversy that continues to the present. One response to the Bush policy was establishment of state stem cell research funding programs, notably the California Institute of Regenerative Medicine (CIRM). As Director of the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) and Vice Chair of the National Institutes of Health (NIH) Stem Cell Task Force, and now as a member of the Empire State Stem Cell Funding Board and member of an Institute of Medicine (IOM) committee charged with evaluation of the CIRM, I have had the opportunity to gain a first-hand perspective of the field. Here I present my impressions of the legal and science policy debates and selectively summarize research progress toward the hoped-for cures.",
author = "Spiegel, {Allen M.}",
year = "2013",
language = "English (US)",
volume = "124",
pages = "94--110",
journal = "Transactions of the American Clinical and Climatological Association",
issn = "0065-7778",
publisher = "American Clinical And Climatological Association",

}

TY - JOUR

T1 - The stem cell wars

T2 - a dispatch from the front.

AU - Spiegel, Allen M.

PY - 2013

Y1 - 2013

N2 - The development of human embryonic stem cell (hESC) lines in 1998 offered the prospect of a new era of regenerative medicine in which cell therapy might cure intractable diseases such as type 1 diabetes, Parkinson's disease, and spinal cord injury. The Bush Administration decision in 2001 to restrict federal funding of hESC research touched off a controversy that continues to the present. One response to the Bush policy was establishment of state stem cell research funding programs, notably the California Institute of Regenerative Medicine (CIRM). As Director of the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) and Vice Chair of the National Institutes of Health (NIH) Stem Cell Task Force, and now as a member of the Empire State Stem Cell Funding Board and member of an Institute of Medicine (IOM) committee charged with evaluation of the CIRM, I have had the opportunity to gain a first-hand perspective of the field. Here I present my impressions of the legal and science policy debates and selectively summarize research progress toward the hoped-for cures.

AB - The development of human embryonic stem cell (hESC) lines in 1998 offered the prospect of a new era of regenerative medicine in which cell therapy might cure intractable diseases such as type 1 diabetes, Parkinson's disease, and spinal cord injury. The Bush Administration decision in 2001 to restrict federal funding of hESC research touched off a controversy that continues to the present. One response to the Bush policy was establishment of state stem cell research funding programs, notably the California Institute of Regenerative Medicine (CIRM). As Director of the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) and Vice Chair of the National Institutes of Health (NIH) Stem Cell Task Force, and now as a member of the Empire State Stem Cell Funding Board and member of an Institute of Medicine (IOM) committee charged with evaluation of the CIRM, I have had the opportunity to gain a first-hand perspective of the field. Here I present my impressions of the legal and science policy debates and selectively summarize research progress toward the hoped-for cures.

UR - http://www.scopus.com/inward/record.url?scp=84895853382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895853382&partnerID=8YFLogxK

M3 - Article

VL - 124

SP - 94

EP - 110

JO - Transactions of the American Clinical and Climatological Association

JF - Transactions of the American Clinical and Climatological Association

SN - 0065-7778

ER -